Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
N4 Pharma PLC - Derbyshire, England-based pharmaceutical company focused on the development of nanoparticle technology - Announces partnership with Glasgow-based University of Strathclyde’s CMAC National Facility, aimed at accelerating development and broadening therapeutic applications. The collaboration combines N4 Pharma’s Nuvec delivery platform with CMAc’s expertise.
CMAC Industry Director Massimo Bresciani says: ‘This project demonstrates the strength of industry-academic partnerships in accelerating medicines manufacturing. By combining N4 Pharma’s innovative delivery platform with CMAC’s technical expertise, we aim to unlock new possibilities in RNA therapeutics.’
Current stock price: 0.71 pence each, closed 2.7% lower on Tuesday in London
12-month change: up 28%
Copyright 2025 Alliance News Ltd. All Rights Reserved.